MX2014010482A - Metodo para la preparacion de vacunas de celulas dendriticas. - Google Patents
Metodo para la preparacion de vacunas de celulas dendriticas.Info
- Publication number
- MX2014010482A MX2014010482A MX2014010482A MX2014010482A MX2014010482A MX 2014010482 A MX2014010482 A MX 2014010482A MX 2014010482 A MX2014010482 A MX 2014010482A MX 2014010482 A MX2014010482 A MX 2014010482A MX 2014010482 A MX2014010482 A MX 2014010482A
- Authority
- MX
- Mexico
- Prior art keywords
- preparation
- dendritic cell
- cell vaccines
- dendritic cells
- relates
- Prior art date
Links
- 229940029030 dendritic cell vaccine Drugs 0.000 title 1
- 210000004443 dendritic cell Anatomy 0.000 abstract 2
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 208000031886 HIV Infections Diseases 0.000 abstract 1
- 208000037357 HIV infectious disease Diseases 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 abstract 1
- 210000001165 lymph node Anatomy 0.000 abstract 1
- 230000001617 migratory effect Effects 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
- 230000035899 viability Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/19—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/24—Antigen-presenting cells [APC]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/46—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/02—Compounds of the arachidonic acid pathway, e.g. prostaglandins, leukotrienes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2301—Interleukin-1 (IL-1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2304—Interleukin-4 (IL-4)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2306—Interleukin-6 (IL-6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/25—Tumour necrosing factors [TNF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Communicable Diseases (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12382078 | 2012-03-02 | ||
| PCT/EP2013/054121 WO2013127976A1 (en) | 2012-03-02 | 2013-03-01 | Method for the preparation of dendritic cell vaccines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2014010482A true MX2014010482A (es) | 2015-04-08 |
Family
ID=47754551
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014010482A MX2014010482A (es) | 2012-03-02 | 2013-03-01 | Metodo para la preparacion de vacunas de celulas dendriticas. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20150125489A1 (enExample) |
| EP (1) | EP2819696A1 (enExample) |
| JP (1) | JP2015513401A (enExample) |
| CN (1) | CN104244975A (enExample) |
| CA (1) | CA2865952A1 (enExample) |
| HK (1) | HK1204275A1 (enExample) |
| IN (1) | IN2014DN07961A (enExample) |
| MX (1) | MX2014010482A (enExample) |
| WO (1) | WO2013127976A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR3018819A1 (fr) * | 2014-03-19 | 2015-09-25 | Univ Bourgogne | Traitement de la reponse inflammatoire et dysimmunitaire |
| CN103948917A (zh) * | 2014-04-02 | 2014-07-30 | 江苏和泽生物科技有限公司 | 树突状细胞疫苗的制备方法 |
| WO2016145317A1 (en) * | 2015-03-12 | 2016-09-15 | Thomas Schwaab | Enrichment of cd16+ monocytes to improve dendritic cell vaccine quality |
| CN105039256A (zh) * | 2015-07-13 | 2015-11-11 | 中政道和（北京）生物科技有限公司 | 一种支气管镜下获取肿瘤组织进行树突细胞培养扩增方法 |
| MX2018003757A (es) * | 2015-09-26 | 2018-09-21 | Primevax Immuno Oncology Inc | Composiciones y metodos para producir celulas dendriticas. |
| JP2018007599A (ja) * | 2016-07-12 | 2018-01-18 | 株式会社ガイアバイオメディシン | 樹状細胞集団の調製方法 |
| CA3082779A1 (en) | 2016-11-16 | 2018-05-24 | PrimeVax Immuno-Oncology, Inc. | Combination immunotherapies for treatment of cancer |
| EP3565567A4 (en) | 2017-01-04 | 2020-07-29 | Primevax Immuno-Oncology, Inc. | COMPOSITIONS AND METHODS OF THERAPY WITH DENGUE VIRUS |
| CN112029724A (zh) * | 2020-09-17 | 2020-12-04 | 和泓尚医(成都)生物科技有限公司 | 一种加速树突状细胞成熟的体外培养方法及其应用 |
| CN113679830B (zh) * | 2021-08-27 | 2023-10-27 | 苏州大学 | 用于肿瘤治疗的复合纳米疫苗及其制备方法 |
| CN113980901B (zh) * | 2021-12-28 | 2022-06-17 | 上海惠盾因泰生物科技有限公司 | 一种制备高纯度的成熟人树突状细胞的方法及应用 |
| CN114377122B (zh) * | 2022-01-18 | 2023-04-07 | 四川大学 | 一种基于四面体框架核酸的复合佐剂、mRNA疫苗及其制备方法和用途 |
| CN117327654A (zh) * | 2022-06-24 | 2024-01-02 | 丽宝生医股份有限公司 | 用于制造成熟树突细胞的方法 |
| EP4544028A4 (en) * | 2022-06-24 | 2026-05-20 | Lihpao Life Science Corp | PROCESS FOR THE PRODUCTION OF MATURE DENDRITIC CELLS |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5017691A (en) | 1986-07-03 | 1991-05-21 | Schering Corporation | Mammalian interleukin-4 |
| KR20020059856A (ko) * | 2001-01-08 | 2002-07-16 | 김철중 | 에이치아이브이 유사입자의 제조 |
| MX2007004028A (es) * | 2004-10-04 | 2007-09-11 | Biovaxim Ltd | Vacunas con virus enteros inactivados con subtipo coincidente para tratar pacientes con infeccion por vih. |
| EP1840206A1 (en) * | 2006-03-28 | 2007-10-03 | Gsf-Forschungszentrum Für Umwelt Und Gesundheit, Gmbh | Compositions for the preparation of mature dendritic cells |
-
2013
- 2013-03-01 JP JP2014559235A patent/JP2015513401A/ja active Pending
- 2013-03-01 CA CA 2865952 patent/CA2865952A1/en not_active Abandoned
- 2013-03-01 HK HK15104845.2A patent/HK1204275A1/xx unknown
- 2013-03-01 US US14/382,398 patent/US20150125489A1/en not_active Abandoned
- 2013-03-01 MX MX2014010482A patent/MX2014010482A/es unknown
- 2013-03-01 EP EP13706563.7A patent/EP2819696A1/en not_active Withdrawn
- 2013-03-01 CN CN201380020366.9A patent/CN104244975A/zh active Pending
- 2013-03-01 WO PCT/EP2013/054121 patent/WO2013127976A1/en not_active Ceased
- 2013-03-01 IN IN7961DEN2014 patent/IN2014DN07961A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN104244975A (zh) | 2014-12-24 |
| JP2015513401A (ja) | 2015-05-14 |
| WO2013127976A1 (en) | 2013-09-06 |
| CA2865952A1 (en) | 2013-09-06 |
| HK1204275A1 (en) | 2015-11-13 |
| EP2819696A1 (en) | 2015-01-07 |
| US20150125489A1 (en) | 2015-05-07 |
| IN2014DN07961A (enExample) | 2015-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014DN07961A (enExample) | ||
| MX2019014009A (es) | Metodos mejorados para la elaboracion de terapias celulares adoptivas. | |
| CL2015002709A1 (es) | Inhibidores macrocíclicos de las interacciones proteína/proteína pd-1/pd-l1 y cd80(b7-1)/pd-l1 | |
| CO2017002719A2 (es) | Anticuerpos anti-glucagón | |
| EA201890942A1 (ru) | Мультивалентные вакцины с синтетическими наноносителями | |
| MX375592B (es) | Composiciones y su uso para tratar hemoglobinopatias. | |
| MX2016003216A (es) | Metodos y composiciones farmaceuticas para el tratamiento de la infeccion por el virus de la hepatitis b. | |
| AR090465A1 (es) | Formas solidas de un profarmaco de nucleotidos de tiofosforamidato | |
| MX2016013747A (es) | Métodos para aislar, cultivar y diseñar genéticamente poblaciones de células inmunes para terapia adoptiva. | |
| MX2016006620A (es) | Receptores de células t humanas con alta afinidad modificados por medio de manipulación genetica. | |
| BR112017001579A2 (pt) | anticorpos anti-cd3, anticorpos anti-cd3 ativáveis, anticorpos anti-cd3 multiespecíficos, anticorpos anti-cd3 ativáveis multiespecíficos e métodos de uso dos mesmos | |
| MX358099B (es) | Anticuerpos que neutralizan el virus de inmunodeficiencia humano y metodos de uso de ellos. | |
| TR201909389T4 (tr) | Terapötik nanopartikülleri hazırlamaya yönelik proses. | |
| CR20170279A (es) | Compuestos de carbamoilpiridona policíclicos y su uso farmacéutico | |
| CR20140365A (es) | Compuestos de carbamato y preparación y uso de los mismos | |
| GT201500046A (es) | Mètodos para el tratamiento de infecciones de hepatitis b y hepatitis d | |
| CO7200270A2 (es) | Azaindolcarboxamidas y azaindoltiocarboxamidas como insecticidas y acaricidas | |
| MX2016016992A (es) | Aptameros especificos de tlr-4 y usos de los mismos. | |
| AR094026A1 (es) | Metodo para activar la celula t helper | |
| MX345351B (es) | Compuesto macrociclico y metodos para su produccion. | |
| MX2018006373A (es) | Produccion de virus en cultivos celulares. | |
| ECSP13012997A (es) | Antídotos anticoagulantes | |
| MX357061B (es) | Diseño de inmunogenos a base de linaje de celulas b con animales humanizados. | |
| EA201500043A1 (ru) | Лекарственная форма для продленного высвобождения действующих веществ | |
| ES2656474T3 (es) | Osteopontina láctea de origen mamífero para potenciar la capacidad de respuesta inmune |